The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis
Histopathology · 2026-12 · 89 (6) · 927-940
DOI: 10.1111/his.70225 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Histopathology, online erschienen am 20.06.2026. Verfasst von Yao Shu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Tumour budding (TB) has been recognized as an additional prognostic factor in the TNM (2017) and WHO (2019) classification systems. However, its prognostic impact in stages II and III colorectal cancer (CRC) remains inconsistently defined. This study aims to systematically evaluate the prognostic value of high‐grade TB in stage II–III CRC. Methods and results A systematic search of PubMed, Embase and Cochrane Library was conducted to identify studies reporting the association between high‐grade TB and survival outcomes in stage II–III CRC. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for disease‐free survival (DFS), overall survival (OS) and cancer‐specific survival (CSS) were calculated using random‐effects models. A total of 43 studies involving 17,831 patients were included. Univariable analysis showed that high‐grade TB was significantly associated with worse DFS (HR 2.53, 95% CI 2.14–3.00), OS (HR 2.40, 95% CI 1.69–3.42) and CSS (HR 3.37, 95% CI 2.19–5.19). Multivariable analysis confirmed the independent prognostic value of high‐grade TB for all three outcomes. Subgroup analysis stratified by TNM stage revealed that high‐grade TB consistently predicted adverse outcomes in both stage II and stage III disease.
Conclusions
This study confirms that high‐grade TB is an independent prognostic factor in stage II–III CRC, consistently associated with worse DFS, OS and CSS. Incorporating TB into routine histopathological assessment may improve risk stratification and help identify high‐risk patients, although its role in guiding therapeutic decisions requires further prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands.
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
ORCID-Profile: Yao Shu, Heng Zhang, Alessandro Lugli, Femke Simmer, Iris D Nagtegaal
Zitieren
APA
Shu, Y., Zhang, H., Lugli, A., Simmer, F., & Nagtegaal, I. D. (2026). The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis. Histopathology, 89(6), 927-940. https://doi.org/10.1111/his.70225
Vancouver
Shu Y, Zhang H, Lugli A, Simmer F, Nagtegaal ID. The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis. Histopathology. 2026;89(6):927-940. doi:10.1111/his.70225
BibTeX
@article{Shu2026,
author = {Shu, Yao and Zhang, Heng and Lugli, Alessandro and Simmer, Femke and Nagtegaal, Iris D},
title = {The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {6},
pages = {927--940},
doi = {10.1111/his.70225}
}
EUVIMED